

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Capplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:29:30 ON 04 FEB 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:29:39 ON 04 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES:      3 FEB 2008    HIGHEST RN 1001389-12-3

DICTIONARY FILE UPDATES:    3 FEB 2008    HIGHEST RN 1001389-12-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007




Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10566799.str



```

chain nodes :
7  8  9  10  11  12  13  14  15  20  21  22  23  24  25  26  27  28  29  30  31  32
 33  34
ring nodes :
1  2  3  4  5  6
chain bonds :
1-15  2-22  2-23  3-24  4-7  5-25  6-20  6-21  7-8  7-14  8-9  8-12  8-13  9-10
9-11  15-34  26-27  26-28  26-29  30-31  31-32  31-33
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  7-14  9-10  9-11  15-34  26-27  26-28  26-29
30-31  31-32  31-33
exact bonds :
1-15  2-22  2-23  3-24  5-25  6-20  6-21  7-8  8-9  8-12  8-13
isolated ring systems :
containing 1 :

```

G1:H,Ak

G2:[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 20:CLASS 21:CLASS 22:CLASS  
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS  
31:CLASS 32:CLASS 33:CLASS 34:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 11:30:01 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 883 TO ITERATE

100.0% PROCESSED 883 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 15878 TO 19442

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 11:30:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 17061 TO ITERATE

100.0% PROCESSED 17061 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

STN INTERNATIONAL LOGOFF AT 11:30:10 ON 04 FEB 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Capplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Capplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:31:50 ON 04 FEB 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:31:59 ON 04 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:      3 FEB 2008    HIGHEST RN 1001389-12-3

DICTIONARY FILE UPDATES:    3 FEB 2008    HIGHEST RN 1001389-12-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10566799a.str



chain nodes :  
 7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 26 27 28 29 30 31 32  
 33 34 40 41 42 43  
 ring nodes :  
 1 2 3 4 5 6 38 39  
 chain bonds :  
 1-15 2-22 2-23 3-24 4-7 5-25 6-20 6-21 7-8 7-14 8-9 8-12 8-13 9-10  
 9-11 15-34 26-27 26-28 26-29 30-31 31-32 31-33 38-40 38-41 39-42 39-43  
 ring bonds :  
 1-2 1-6 2-3 3-4 3-39 4-5 5-6 5-38 38-39  
 exact/norm bonds :  
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-14 9-10 9-11 15-34 26-27 26-28 26-29  
 30-31 31-32 31-33  
 exact bonds :  
 1-15 2-22 2-23 3-24 3-39 5-25 5-38 6-20 6-21 7-8 8-9 8-12 8-13 38-39  
 38-40 38-41 39-42 39-43  
 isolated ring systems :  
 containing 1 :

G1:H,Ak

G2:[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 20:CLASS 21:CLASS 22:CLASS  
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS  
31:CLASS 32:CLASS 33:CLASS 34:CLASS 38:Atom 39:Atom 40:CLASS 41:CLASS  
42:CLASS 43:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:32:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 146 TO 694

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:32:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 451 TO ITERATE

100.0% PROCESSED 451 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

STN INTERNATIONAL LOGOFF AT 11:32:28 ON 04 FEB 2008



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Capplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:34:40 ON 04 FEB 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:34:51 ON 04 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES:      3 FEB 2008    HIGHEST RN 1001389-12-3

DICTIONARY FILE UPDATES:    3 FEB 2008    HIGHEST RN 1001389-12-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10566799c.str



chain nodes :  
 7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 28 29 30 31 32  
 ring nodes :  
 1 2 3 4 5 6 26 27  
 chain bonds :  
 1-15 2-22 2-23 3-24 4-7 5-25 6-20 6-21 7-8 7-14 8-9 8-12 8-13 9-10  
 9-11 15-32 26-28 26-29 27-30 27-31  
 ring bonds :  
 1-2 1-6 2-3 3-4 3-27 4-5 5-6 5-26 26-27  
 exact/norm bonds :  
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-14 9-10 9-11 15-32  
 exact bonds :  
 1-15 2-22 2-23 3-24 3-27 5-25 5-26 6-20 6-21 7-8 8-9 8-12 8-13 26-27  
 26-28 26-29 27-30 27-31  
 isolated ring systems :  
 containing 1 :

G1:H,Ak

G2:S,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 20:CLASS 21:CLASS 22:CLASS  
23:CLASS 24:CLASS 25:CLASS 26:Atom 27:Atom 28:CLASS 29:CLASS 30:CLASS  
31:CLASS 32:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak

G2 S, N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:35:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 2671 TO 4249

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:35:13 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3521 TO ITERATE

100.0% PROCESSED 3521 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L3                    0 SEA SSS FUL L1

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

STN INTERNATIONAL LOGOFF AT 11:35:18 ON 04 FEB 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Capplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Capplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:41:19 ON 04 FEB 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:41:29 ON 04 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3  
DICTIONARY FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10566799.str



chain nodes :  
 7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 26 28  
 ring nodes :  
 1 2 3 4 5 6  
 chain bonds :  
 1-15 1-28 2-22 2-23 3-24 4-7 5-25 6-20 6-21 7-8 7-14 8-9 8-12 8-13  
 9-10 9-11 15-26  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 exact/norm bonds :  
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-14 9-10 9-11 15-26  
 exact bonds :  
 1-15 1-28 2-22 2-23 3-24 5-25 6-20 6-21 7-8 8-9 8-12 8-13  
 isolated ring systems :  
 containing 1 :

G1:H,Ak

G2:S,N

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 20:CLASS 21:CLASS 22:CLASS  
 23:CLASS 24:CLASS 25:CLASS 26:CLASS 28:CLASS




L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak

G2 S, N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:41:50 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 14395 TO ITERATE

13.9% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 280713 TO 295087  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:41:55 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 284933 TO ITERATE

100.0% PROCESSED 284933 ITERATIONS  
SEARCH TIME: 00.00.04

37 ANSWERS

L3 37 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

178.36

178.57

FILE 'CAPLUS' ENTERED AT 11:42:04 ON 04 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Feb 2008 VOL 148 ISS 6  
FILE LAST UPDATED: 3 Feb 2008 (20080203/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full

L4            14 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1395785 CAPLUS

DOCUMENT NUMBER: 148:55084

TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Lebroli, Marc; Keertikar, Kartik M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 497pp., Cont.-in-part of U.S. Ser. No. 710,644.

DOCUMENT TYPE: CODEN: USXXCO

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: English

PATENT INFORMATION: 7


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007281951	A1	20071206	US 2007-788856	20070420
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 2007037824	A1	20070215	US 2004-776988	20040211
US 2004209878	A1	20041021	US 2005-245401	20051006
US 7119200	B2	20061010	US 2007-710644	20070223
US 2006128725	A1	20060615	US 2002-408027P	20020904
US 7196078	B2	20070327	US 2002-421959P	20021029
ZA 2005001855	A	20060329	US 2003-654546	A2 20030903
US 2007225270	A1	20070927	US 2004-776988	A2 20040211
			US 2005-245401	A3 20051006
			US 2007-710644	A2 20070223
			CN 2003-824997	A3 20030903

OTHER SOURCE(S): MARPAT 148:55084


GI

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs

such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I, alone or in combination with other therapeutic agent, is claimed.

IT 677286-93-OP  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

RN 677286-93-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[(1-{3-phenylbutyl}-4-piperidinyl)methyl]- (CA INDEX NAME)

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)



L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:359039 CAPLUS

DOCUMENT NUMBER: 146:379835

TITLE: Preparation of cyanopyridones as survivin inhibitors

INVENTOR(S): Wendt, Michael D.; Sun, Chaohong; Sauer, Daryl R.; Elmore, Steven W.; Kunzer, Aaron R.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35pp.

DOCUMENT TYPE: CODEN: USXXCO

LANGUAGE: Patent


FAMILY ACC. NUM. COUNT: English

PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007072833	A1	20070329	US 2006-529845	20060929
PRIORITY APPLN. INFO.:			US 2005-721634P	P 20050929

OTHER SOURCE(S): MARPAT 146:379835

GI



I

AB Title compds. [I; A1, B1 = R1, OR1, SOR1, SO2R1, COR1, CO2R1, NHCOR1, SO2NHR1, NHCOR1, etc.; R1 = (fused) Ph, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, (substituted) alkyl, alkenyl, alkynyl], were prepared. Thus, 5-bromo-2-hydroxyacetophenone,

4-methylbenzaldehyde, Et cyanoacetate, and ammonium acetate were refluxed together in EtOH for 6 h to give

6-(5-bromo-2-hydroxyphenyl)-4-(4-methylphenyl)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile. I bound to survivin with binding affinities of 0.037-29 μM.


IT 931113-30-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyanopyridones as survivin inhibitors)

RN 931113-30-3 CAPLUS

CN 4-Piperidinecarboxamide, N-[(5-chloro-3-{4-(2-chloro-5-(trifluoromethyl)phenyl)-5-cyano-1,6-dihydro-6-oxo-2-pyridinyl}-2-hydroxyphenyl)methyl]-N-methyl-1-[3-(5-methyl-2-furanyl)butyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

-CF<sub>3</sub>

ACCESSION NUMBER: 2006:579598 CAPLUS  
DOCUMENT NUMBER: 145:62916  
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent

INVENTOR(S): Gazi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.  
PATENT ASSIGNEE(S): Schering Corporation, USA  
SOURCE: U.S. Pat. Appl. Publ., 1068 pp., Cont.-in-part of U.S.

Ser. No. 776,988.

CODEN: USXXCO

Patent

English

7

DOCUMENT TYPE:

LANGUAGE:




FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006128725	A1	20060615	US 2005-245401	20051006
US 7196078	B2	20070327		
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 2007037824	A1	20070215		
US 2004209878	A1	20041021	US 2004-776988	20040211
US 7119200	B2	20061010		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
US 2007072881	A1	20070329	US 2006-542920	20061004
WO 2007044449	A2	20070419	WO 2006-US38939	20061004
WO 2007044449	A3	20070524		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 2007225270	A1	20070927	US 2007-710644	20070223
US 2007281951	A1	20071206	US 2007-788856	20070420
PRIORITY APPLN. INFO.:				US 2002-408027P
				P 20020904
				US 2002-421959P
				P 20021029
				US 2003-654546
				A2 20030903
				US 2004-776988
				A2 20040211
				CN 2003-824997
				A3 20030903
				US 2005-245401
				A2 20051006
				US 2007-710644
				A2 20070223

OTHER SOURCE(S): MARPAT 145:62916

GI



II

III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs

such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed.


IT 677286-93-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

RN 677286-93-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[(1-(3-phenylbutyl)-4-piperidinyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2004:981365 CAPLUS

DOCUMENT NUMBER:

141:379943

TITLE:

Preparation of pyrazolopyrimidines as

cyclin-dependent

INVENTOR(S):

Kinase inhibitors  
Ouzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;  
Doll, Ronald J.; Girijavallabhan, Vilyoor M.;

Mallams,

Alan; Alvarez, Carmen S.; Keertikar, Kartik M.;  
Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent;  
Fischmann, Thierry O.; Dillard, Lawrence W.; Tran,  
Vinh D.; He, Zhen Min; James, Ray Anthony; Park,  
Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas  
Walsh

PATENT ASSIGNEE(S):

Schering Corporation, USA; Pharmacoepia, Inc.  
U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of

U.S.

Ser. No. 654,546.

DOCUMENT TYPE:

CODEN: USXXCO

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT:

English

PATENT INFORMATION:



6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209878	A1	20041021	US 2004-776988	20040211
US 2004209878	A1	20041021	US 2004-776988	20040211
PRIORITY APPLN. INFO.:			US 2002-408027P	P 20020904
			US 2002-421959P	P 20021029
			US 2003-654546	A2 20030903
			US 2004-776988	A 20040211

GI

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)



AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the

CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 µM and 0.029 µM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a Part

III of I-III series.

IT

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)


(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

RN 677286-93-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[(1-(3-phenylbutyl)-4-piperidinyl)methyl]- (CA INDEX NAME)

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)



L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2004:546499 CAPLUS

DOCUMENT NUMBER:

141:106377

TITLE:

A preparation of novel piperidine derivatives as modulators of chemokine receptor CCR5

INVENTOR(S):

Oldfield, John; Tucker, Howard

PATENT ASSIGNEE(S):

Astrazeneca Ab, Swed.

SOURCE:

PCT Int. Appl., 60 pp.

DOCUMENT TYPE:

CODEN: PIXXD2

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT:

English



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056808	A1	20040708	WO 2003-SE2005	20031218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SE, SZ, TG, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,			
TG	AU 2003288853	A1	20040714	AU 2003-288853
	EP 1572683	A1	20050914	EP 2003-781232
	EP 1572683	B1	20061018	20031218
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	JP 2006512364	T	20060413	JP 2004-562205
	AT 342898	T	20061115	AT 2003-781232
	ES 2274295	T3	20070516	ES 2003-781232
	US 2006069120	A1	20060330	US 2005-539522
PRIORITY APPLN. INFO.:			SE 2002-1820	A 20021220
			WO 2003-SE2005	W 20031218

OTHER SOURCE(S):

MARPAT 141:106377

GI




AB The invention relates to a preparation of novel piperidine derivs. of formula I  
[wherein: A is absent or (CH<sub>2</sub>)<sub>2</sub>; R<sub>1</sub> is alkyl, C(O)NH-alkyl, or CO<sub>2</sub>-alkyl, etc.; R<sub>2</sub> is alkyl, Ph, heteroaryl, or cycloalkyl; R<sub>3</sub> is H or alkyl; R<sub>4</sub> is (hetero)aryl; R<sub>5</sub> is H or alkyl; X is (CH<sub>2</sub>)<sub>1-2</sub>, CH:CH, OCH<sub>2</sub>, or S(O)O-2CH<sub>2</sub>], useful as modulators of chemokine receptor CCR5. The invention compds. are claimed to be useful for the treatment of CCR5-mediated diseases such as autoimmune, inflammatory, or proliferative diseases. The ability of the invention compds. to inhibit the binding of RANTES and MIP-1α was assessed (certain compds. of formula I have IC<sub>50</sub> < 50 μM). For instance, Pic50 (neg. log of the IC<sub>50</sub> result) for piperidine derivative II was determined as 7.92 (MIP-1α binding inhibition).

IT 718637-51-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of novel piperidine derivs. as modulators

of chemokine receptor CCR5)  
RN 718637-51-5 CAPLUS  
CN 4-piperidineacetamide, N-(4-fluorophenyl)-1-[(3S)-3-hydroxy-3-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




ACCESSION NUMBER: 2004:546479 CAPLUS  
DOCUMENT NUMBER: 141:106374  
TITLE: A preparation of novel piperidine derivatives as modulators of chemokine receptor CCR5  
INVENTOR(S): Cumming, John; Fauli, Alan; Fielding, Colin; Oldfield.  
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.  
SOURCE: PCT Int. Appl., 118 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056773	A1	20040708	WO 2003-SE2008	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG				
CA 2508624	A1	20040708	CA 2003-2508624	20031218
AU 2003288856	A1	20040714	AU 2003-288856	20031218
EP 1572650	A1	20050914	EP 2003-781235	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017459	A	20051116	BR 2003-17459	20031218
CN 1732153	A	20060208	CN 2003-80107833	20031218
JP 2006514107	T	20060427	JP 2005-502630	20031218
IN 2005DN2442	A	20070406	IN 2005-DN2442	20050607
MX 2005PA06381	A	20050829	MX 2005-PA6381	20050614
US 2006189650	A1	20060824	US 2005-519859	20050617
NO 2005003539	A	20050920	NO 2005-3539	20050719
ZA 2005004616	A	20060329	ZA 2005-4616	20060116
PRIORITY APPLN. INFO.:				
			SE 2002-3821	A 20021220
			SE 2003-499	A 20030224
			SE 2003-1425	A 20030515
			WO 2003-SE2008	W 20031218



OTHER SOURCE(S): MHPAT 141:106374  
GI

IT 718637-41-5  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant; preparation of novel piperidine derivs. as modulators of chemokine receptor CCR5)  
RN 718637-41-5 CAPLUS  
CN 4-piperidineacetamide, 1-[(3R)-3-chloro-3-phenylpropyl]-N-(4-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT




AB The invention relates to a preparation of novel piperidine derivs. of formula I  
[wherein: A is absent or (CH<sub>2</sub>)<sub>2</sub>; R<sub>1</sub> is alkyl, C(O)NH-alkyl, or CO<sub>2</sub>-alkyl, etc.; R<sub>2</sub> is alkyl, Ph, heteroaryl, or cycloalkyl; R<sub>3</sub> is H or alkyl; R<sub>4</sub> is (hetero)aryl or (cyclo)alkyl; X is O or S(O)O-2], useful as modulators of chemokine receptor CCR5. The invention compds. are claimed to be useful for the treatment of CCR5-mediated diseases such as autoimmune, inflammatory, or proliferative diseases. The invention compds. are also

of value in inhibiting the entry of viruses (such as HIV) into target cells (no biol. data). The ability of the invention compds. to inhibit the binding of RANTES and MIP-1α was assessed (certain compds. of formula I have IC<sub>50</sub> < 50 μM). For instance, Pic50 (neg. log of the IC<sub>50</sub> result) for piperidine derivative II was determined as 6.91 (table


XV).  
IT 718610-18-5P 718611-68-8P 718611-69-9P  
718611-70-2P 718611-71-3P 718611-72-4P  
718611-73-5P 718612-04-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel piperidine derivs. as modulators of chemokine receptor ccr5)  
RN 718610-18-5 CAPLUS  
CN Benzamide, 4-chloro-N-[(1S)-3-[4-[2-[(4-methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-68-8 CAPLUS  
CN Propanamide, 3,3,3-trifluoro-N-((1S)-3-[4-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-69-9 CAPLUS  
CN Propanamide, 3,3,3-trifluoro-N-((1S)-3-[4-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-70-2 CAPLUS  
CN Propanamide, 3,3,3-trifluoro-N-((1S)-3-[4-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-71-3 CAPLUS  
CN Butanamide, 4,4,4-trifluoro-N-((1S)-3-[4-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-72-4 CAPLUS  
CN Cyclobutanecarboxamide, 3,3-difluoro-N-((1S)-3-[4-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-73-5 CAPLUS  
CN Cyclobutanecarboxamide, 4,4-difluoro-N-((1S)-3-[4-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl)-1-phenylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-04-5 CAPLUS  
CN Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-[4-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl)-1-phenylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 718610-15-2P 718610-19-6P 718610-23-2P  
718610-66-3P 718610-69-6P 718611-16-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of novel piperidine derivs. as modulators of chemokine receptor Ccr5)

RN 718610-15-2 CAPLUS  
CN Piperidine, 1-(3-chloro-3-phenylpropyl)-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)




RN 718610-19-6 CAPLUS  
CN 1-Piperidinepropanamine, 4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-α-phenyl-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 718610-23-2 CAPLUS  
CN Piperidine, 1-(3-chloro-3-phenylpropyl)-4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]- (CA INDEX NAME)




RN 718610-66-3 CAPLUS  
CN 1-Piperidinepropanol, 4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-α-phenyl-, (αS)- (CA INDEX NAME)



RN 718610-69-6 CAPLUS  
CN 1-Piperidinepropanol, 4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-α-phenyl-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 718611-16-6 CAPLUS

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN Carbamic acid,  
 [(1S)-3-[4-[2-[[4-(methylsulfonyl)phenyl]sulfonyl]ethyl]-1-  
 piperidinyl]-1-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:265849 CAPLUS  
 DOCUMENT NUMBER: 140:321371  
 TITLE: Preparation of pyrazolopyrimidines as  
 cyclin-dependent

INVENTOR(S):

Kinase inhibitors  
 Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;  
 Doll, Ronald J.; Girijavallabhan, Vidyoor Moopil;  
 Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik  
 M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent;  
 Fischmann, Thierry O.; Dillard, Lawrence W.; Tran,  
 Vinh D.; He, Zhen Min; James, Ray Anthony; Park,  
 Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas  
 Walsh

PATENT ASSIGNEE(S):  
 SOURCE: Schering Corporation, USA  
 PCT Int. Appl., 609 pp.


DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 English

FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022561	A1	20040318	WO 2003-XB27555	20030901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, ZW, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1735614	A	20060215	CN 2003-824997	20030903
CN 1880317	A	20061220	CN 2006-10101322	20030903
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
PRIORITY APPLN. INFO.:			US 2002-421959P	P 20021029
			CN 2003-824997	A3 20030903

GI

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020  $\mu$ M and 0.029  $\mu$ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a Part III of I-III series.

IT 677286-93-OP  
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
 (preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

RN 677286-93-0 CAPLUS  
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[[1-(3-phenylbutyl)-4-piperidinyl]methyl]- (CA INDEX NAME)

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)





L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:754342 CAPLUS  
DOCUMENT NUMBER: 137:263068  
TITLE: Preparation of aryl and biaryl derivatives having Melanin-concentrating hormone modulatory activity  
INVENTOR(S): Hobbs, Douglas W.; Guo, Tao; Hunter, Rachael C.; Gu, Huizhong  
PATENT ASSIGNEE(S): Pharmacopeia, Inc., USA  
SOURCE: PCT Int. Appl., 180 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076929	A1	20021003	WO 2002-US8300	20020319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, HR, NE, SN, TD, TG				
CA 2441235	A1	20021003	CA 2002-2441235	20020319
AU 2002247367	A1	20021008	AU 2002-247367	20020319
US 2003092715	A1	20030515	US 2002-101136	20020319
US 7034056	B2	20060425		
EP 1370520	A1	20031217	EP 2002-715150	20020319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1498205	A	20040519	CN 2002-806895	20020319
HU 2004000252	A2	20040830	HU 2004-252	20020319
JP 2004526736	T	20040902	JP 2002-576192	20020319
NZ 527680	A	20050729	NZ 2002-527680	20020319
ZA 2003006727	A	20041129	ZA 2003-6727	20030828
MX 2003PA08484	A	20031208	MX 2003-PA8484	20030919
PRIORITY APPLN. INFO.:			US 2001-277534P	P 20010321
			WO 2002-US8300	W 20020319

OTHER SOURCE(S): MARPAT 137:263068  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; A = (un)substituted aryl, pyridinyl, pyrazinyl, pyridazinyl; Z = biphenylcarbamoyl, biphenylcarbonyl, biphenoxycarbonyl, biphenyl, biphenylsulfonyle; M = H, Me, Et, iso-Pr, n-Pr, cyclobutyl; n = 2-4; p = 1-6; R1 = NH2, NHR, NR2, NOR2, NH(CH2)nNR2; R = Me, Et, n-Pr, iso-Pr, cyclobutyl; R2 = H, alkyl] are prepared as antagonists of the Melanin-concentrating hormone (MCH) receptor. In one embodiment, this invention provides methods of preparing title compds., pharmaceutical compns. containing one or more of title compds., methods of preparing pharmaceutical

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2001:177400 CAPLUS  
DOCUMENT NUMBER: 135:5510  
TITLE: Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors  
AUTHOR(S): Ting, P. C.; Lee, J. F.; Anthes, J. C.; Shih, N.-Y.; Piwinski, J. J.  
CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033-1300, USA  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(4), 491-494  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 135:5510  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4(Z)-(methoxyimino)pentyl-1-piperidines, e.g. I and II, were prepared the their NK1 and NK2 receptor activity was evaluated. Compds. I and II were among 5 of the most potent inhibitors. A series of 4(Z)-(methoxyimino)pentyl-1-piperidines was prepared, and their biol. activity as dual NK1/NK2 receptor antagonists determined  
IT 340962-38-1P 340962-41-6P 340962-43-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors)  
RN 340962-38-1 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[(4Z)-5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4-(methoxyimino)pentyl]- (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
formulations comprising one or more title compds., and methods of treatment, prevention or amelioration or one or more of diseases assoc. with the MCH receptor. Thus, the title compd. II was an illustrative inventive compd.  
IT 463940-44-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of aryl and biaryl derivs. having Melanin-concentrating hormone modulatory activity)  
RN 463940-44-5 CAPLUS  
CN Benzamide, N-(2-(3,4-dichlorophenyl)-4-[(1-(hydroxymethyl)cyclopentyl)amino]methyl]-1-piperidinyl)butyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 340962-41-6 CAPLUS  
CN Benzamide, N-[(1-(4Z)-5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4-(methoxyimino)pentyl]-4-piperidinyl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A



RN 340962-43-8 CAPLUS  
 CN 2-Pentanone, 1-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-[(3,4-dichlorophenyl)-5-[4-[[1-(hydroxymethyl)cyclopentyl]amino]methyl]-1-piperidiny]-, O-methylloxime, (2Z)- (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:659363 CAPLUS  
 DOCUMENT NUMBER: 131:271485  
 TITLE: Preparation of biocidal benzylbiphenyl derivatives  
 INVENTOR(S): Meerpoel, Lieven; Van Der Flaas, Mark Arthur Josepha;  
 Van Der Veken, Louis Jozef Elisabeth; Heeres, Jan  
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.  
 SOURCE: PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951578	A1	19991014	WO 1999-EP2098	19990325
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 245763	B	20051221	TW 1999-88103906	19990315
CA 2326159	A1	19991014	CA 1999-2326159	19990325
AU 9933325	A	19991025	AU 1999-33325	19990325
AU 759157	B2	20030410		
BR 9909344	A	20001212	BR 1999-9344	19990325
EP 1066259	A1	20010110	EP 1999-914550	19990325
EP 1066259	B1	20070110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200002846	T2	20010122	TR 2000-2846	19990325
JP 2002510677	T	20020409	JP 2000-542299	19990325
CN 1110478	B	20030604	CN 1999-804494	19990325
NZ 507024	A	20030725	NZ 1999-507024	19990325
RU 2218333	C2	20031210	RU 2000-127729	19990325
IL 138736	A	20050831	IL 1999-138736	19990325
PL 193580	B1	20070228	PL 1999-3432	19990325
ES 2280117	T3	20070901	ES 1999-914550	19990325
US 6440440	B1	20020827	US 2000-647015	20000922
ZA 2000005237	A	20010928	ZA 2000-5237	20000928
IN 2000MN00450	A	20050318	IN 2000-MN450	20000928
NO 2000004905	A	20000929	NO 2000-4905	20000929
NO 317784	B1	20041213		
MX 2000PA09617	A	20010405	MX 2000-PA9617	20000929
PRIORITY APPLN. INFO.:			EP 1998-201043	A 19980402
			WO 1999-EP2098	W 19990325

OTHER SOURCE(S): MARPAT 131:271485  
 GI



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB The title compds. I [dotted line is an optional bond; X is a direct bond when the dotted line represents a bond, or X is hydrogen or hydroxy, when the dotted line does not represent a bond; R1, R2, R5 and R6 are each independently selected from hydrogen, halo, hydroxy, Cl-4alkyl, Cl-4alkyloxy, -SO3H, etc.; R3 and R4 are each independently selected from hydrogen, halo, hydroxy, Cl-4alkyl, Cl-4alkyloxy, nitro, amino, cyano, trifluoromethyl, or trifluoromethoxy; L is a radical of formula Q, Q1, etc.]. Biocides, were prepared E.G., 4-[[[1,1'-biphenyl]-4-yl]1(4-fluorophenyl)methylene]-(1,1'-bipiperidine) dihydrochloride was prepared. Biocidal activities of I were tested toward bacteria, e.g. E. coli, and yeast.

IT 245551-86-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Preparation of biocidal benzylbiphenyl derivs.)

RN 245551-86-4 CAPLUS  
 CN 1-Piperidinepropanol, alpha-[[1,1'-biphenyl]-4-yl]-alpha-(2,4-dichlorophenyl)-4-[2-(dimethylamino)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:576930 CAPLUS  
 DOCUMENT NUMBER: 131:199712  
 TITLE: Preparation of heterocyclic compounds as glycine transport inhibitors  
 INVENTOR(S): Luyten, Walter Herman Maria Louis; Janssens, Frans  
 PATENT ASSIGNEE(S): Eduard; Kennis, Ludo Edmond Josephine  
 SOURCE: Janssen Pharmaceutica N.V., Belg.  
 PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945011	A1	19990910	WO 1999-EP1308	19990226
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, ML, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2322136	A1	19990910	CA 1999-2322136	19990226
AU 9932544	A	19990920	AU 1999-32544	19990226
BR 9907953	A	20001024	BR 1999-7953	19990226
EP 1058684	A1	20001213	EP 1999-937930	19990226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200002570	T2	20001221	TR 2000-2570	19990226
HU 2001001281	A2	20010928	HU 2001-1281	19990226
HU 2001001281	A3	20011128		
EE 200000483	A	20020215	EE 2000-483	19990226
JP 2002050332	T	20020219	JP 2000-534553	19990226
IN 2000MN00192	A	20050304	IN 2000-MN192	20000718
HR 2000000524	A1	20010228	HR 2000-524	20000802
BG 104686	A	20010430	BG 2000-104686	20000811
NO 2000004432	A	20001012	NO 2000-4432	20000905
MX 2000PA08692	A	20010328	MX 2000-PA8692	20000905
PRIORITY APPLN. INFO.:			EP 1998-200700	19980306
			WO 1999-EP1308	W 19990226

OTHER SOURCE(S): MARPAT 131:199712  
 GI




AB The present invention is concerned with the use of glycine transport inhibiting  $\alpha,\alpha$ -diphenyl-1-piperidinebutanamides for the preparation of medicaments, title compds. I (R1, R2, = H, alkyl; X = CR4R5; R4 = H, OH, etc.; R5 = diarylmethoxyalkyl, etc) for treating disorders of the central and peripheral nervous system, in particular psychoses, pain, epilepsy, neurodegenerative diseases (Alzheimer's disease), stroke, head trauma, multiple sclerosis and the like. The title compound II was prepared

Formulations are given. The invention further comprises novel compds., their preparation and their pharmaceutical forms. The bioactivity of II was demonstrated.


IT 241130-18-7P 241130-20-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclic compds. as glycine transport inhibitors)

RN 241130-18-7 CAPLUS  
 CN 1-Piperidinebutanamide, 4-(((cyclohexylphenylmethyl)amino)carbonyl)-N,N-dimethyl- $\alpha,\alpha$ -diphenyl- (CA INDEX NAME)



RN 241130-20-1 CAPLUS  
 CN 1-Piperidinebutanamide, 4-(((diphenylmethyl)amino)carbonyl)-N,N-dimethyl-

$\alpha,\alpha$ -diphenyl- (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

ACCESSION NUMBER: 1999:96124 CAPLUS  
 DOCUMENT NUMBER: 130:168242  
 TITLE: Preparation of 1-(4-sulfamidobutyl)piperidines and related compounds as modulators of chemokine receptor activity.  
 INVENTOR(S): Caldwell, Charles G.; Finke, Paul E.; Maccoss, Malcolm; Meurer, Laura C.; Mills, Sander G.; Oates, Bryan  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 281 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9904794	A1	19990204	WO 1998-US14990	19980721
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SE, SG, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2296314	A1	19990204	CA 1998-2296314	19980721
AU 9885760	A	19990216	AU 1998-85760	19980721
EP 1003514	A1	20000531	EP 1998-936920	19980721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, MC, PT, IE, FI				
US 6136827	A	20001024	US 1998-120010	19980721
JP 2002510327	T	20020402	JP 1999-509949	19980721
PRIORITY APPLN. INFO.:			US 1997-53754P	P 19970725
			GB 1998-958	A 19980116
			WO 1998-US14990	W 19980721


OTHER SOURCE(S): MARPAT 130:168242  
 GI




AB Title compds. (I; R1 = (substituted) alkyl; R2 = H, OH, alkyl, alkoxy, Ph, NMeCONHMe, NHC(=O)Me, Ac; R3 = aryl, aralkyl, aralkoxyalkyl, (substituted) aralkoxyalkyl, aralkoxyamino, etc.), were prepared for treatment of AIDS (no data).

Thus, N-(2-phenyl-4-oxobut-1-yl)-N-methylbenzenesulfonamide (preparation given) was stirred 20 min. with 4-phenylpiperidine, HOAc, and 3A mol. sieves in THF; Na triacetoxycarbonylborohydride was added and the mixture was kept 16 h to give N-[2-phenyl-4-(4-phenylpiperidin-1-yl)but-1-yl]-N-

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 methylbenzenesulfonamide hydrochloride.  
 IT 220392-77-8P 220392-78-9P 220393-25-9P  
 220393-49-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 1-(4-sulfamidoethyl)piperidines and related compds.  
 as  
 modulators of chemokine receptor activity)  
 RN 220392-77-8 CAPLUS  
 CN 4-Piperidinecarboxamide,  
 1-[4-(methyl(phenylsulfonyl)amino)-3-phenylbutyl]-  
 N-pentyl- (CA INDEX NAME)




RN 220392-78-9 CAPLUS  
 CN 4-Piperidinecarboxamide, N-(1-methylethyl)-1-[4-(methyl(phenylsulfonyl)amino)-3-phenylbutyl]- (CA INDEX NAME)




RN 220393-25-9 CAPLUS  
 CN 4-Piperidinecarboxamide,  
 N,N-diethyl-1-[4-(methyl(phenylsulfonyl)amino)-3-phenylbutyl]- (CA INDEX NAME)

L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1998:515956 CAPLUS  
 DOCUMENT NUMBER: 129:225292  
 TITLE: 4-Alkylpiperidines related to SR-48968: potent antagonists of the neurokinin-2 (NK2) receptor  
 AUTHOR(S): Jacobs, Robert T.; Shenvi, Ashok B.; Mauger, Russell C.; Ulatowski, Terrance G.; Aharony, David; Buckner, Carl K.  
 CORPORATE SOURCE: Department of Medicinal Chemistry, a Business Unit of ZENECA, Inc., ZENECA Pharmaceuticals, Wilmington, DE, 19850-5437, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1998), 8(14), 1935-1940  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A series of 4-alkylpiperidine derivs. related to the potent neurokinin-2 (NK2) receptor antagonist SR-48968 (1) is described. Simple aliphatic derivs. were found to be poorly active, but appropriate placement of an alc. functional group afforded compds. that were of similar activity to 1.  
 Several representatives in this series, such as the 4-(1-hydroxy-1-ethylpropyl)piperidine (14), were found to exhibit oral activity in a model of labored abdominal breathing in guinea pigs. These results expand the latitude of substituents available in this region of this series of NK2 receptor antagonists.  
 IT 212910-73-1  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (NK2 receptor antagonist activity of 4-Alkylpiperidines related to SR-48968)  
 RN 212910-73-1 CAPLUS  
 CN Benzamide, N-[4-[4-[2-(acetamino)ethyl]-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl- (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 220393-49-7 CAPLUS  
 CN 4-Piperidinecarboxamide, N-(1,1-dimethylethyl)-1-[4-(methyl(phenylsulfonyl)amino)-3-phenylbutyl]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1995:346893 CAPLUS  
 DOCUMENT NUMBER: 122:132987  
 TITLE: Preparation of N-alkyl-substituted piperidines with neurokinin receptor antagonist activity.  
 INVENTOR(S): Jacobs, Robert Toms; Shenvi, Ashokkumar Bhikkappa  
 PATENT ASSIGNEE(S): Zeneca Ltd., UK  
 SOURCE: Eur. Pat. Appl., 27 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 625509	A1	19941123	EP 1994-303449	19940513
EP 625509	B1	19970710		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT.

SE


CA	2123636	A1	19941118	CA 1994-2123636	19940516
US	5521199	A	19960528	US 1994-242949	19940516
JP	06340624	A	19941213	JP 1994-137780	19940517
JP	3394819	B2	20030407		

PRIORITY APPLN. INFO.: GB 1993-10066 A 19930517

OTHER SOURCE(S): MARPAT 122:132987  
 GI




AB The title compds. (1; Q = (un)substituted Ph, (un)substituted thienyl, (un)substituted imidazolyl, (un)substituted naphthyl, etc.; Q1 = H, Cl-3 alkyl; Q2 = (un)substituted aryl or heteroaryl; R = (un)substituted Cl-8 alkyl or C3-6 cycloalkyl; \* = an optional chiral center), useful as neurokinin 2 receptor antagonists, useful for the treatment of asthma (no data), are prepared and i-containing formulations presented. Thus, N-[2-(3,4-dichlorophenyl)-4-[4-(2-acetoxyethyl)piperidino]butyl]-N-methylbenzamide hydrochloride, m.p. 62-71°, was prepared from 4-(2-acetoxyethyl)piperidine and demonstrated Ki 40 nM to guinea pig-derived NKA receptors.  
 IT 160809-53-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of N-alkyl-substituted piperidines with neurokinin receptor antagonist activity)  
 RN 160809-53-0 CAPLUS  
 CN Benzamide, N-[4-[4-[2-(acetamino)ethyl]-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 160809-36-9P 160809-44-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of N-alkyl-substituted piperidines with neurokinin  
 receptor antagonist activity)

RN 160809-36-9 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[4-(benzoylmethylamino)-3-(3,4-  
 dichlorophenyl)butyl]-N-methoxy-N-methyl- (CA INDEX NAME)



RN 160809-44-9 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[4-(benzoylmethylamino)-3-(3,4-  
 dichlorophenyl)butyl]-N-methoxy-N-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 11:41:19 ON 04 FEB 2008)

FILE 'REGISTRY' ENTERED AT 11:41:29 ON 04 FEB 2008

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 37 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:42:04 ON 04 FEB 2008

L4 14 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

79.18

257.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-11.20

-11.20

STN INTERNATIONAL LOGOFF AT 11:45:55 ON 04 FEB 2008